Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: Cassette (50) performs assays, e.g. multiplexed protein biomarker assays. Wide, bubble-free, slow flows are produced from liquids stored on cassette (50), flowing over wide array (20) of ligand receptors on a capture surface. Flows of Reynolds Number less than about 1, preferably 1×10?1 to 5×10?3, are heated in region (34) preceding and including bubble removal system (128). Analyte is introduced through compressed septum (32). External actuations of displacement pumps (30, 37) and valves (137 A, B, and C) produce flows in response to flow-front optical sensors (150, 152). Elastic sheet provides pump and valve diaphragms and resilient expansion of mixing volume (131). Break-away cover portions are pistons. Heating is by conduction through cassette from external contact heater. Planar cassette body, when tilted from horizontal, enables upward flow from pumped storage (134, 135) to reaction (133) to waste (139), with buoyancy bubble removal before reaction.

Abstract: Cassette (50) performs assays, e.g. multiplexed protein biomarker assays. Wide, bubble-free, slow flows are produced from liquids stored on cassette (50), flowing over wide array (20) of ligand receptors on a capture surface. Flows of Reynolds Number less than about 1, preferably 1×10?1 to 5×10?3, are heated in region (34) preceding and including bubble removal system (128). Analyte is introduced through compressed septum (32). External actuations of displacement pumps (30, 37) and valves (137 A, B, and C) produce flows in response to flow-front optical sensors (150, 152). Elastic sheet provides pump and valve diaphragms and resilient expansion of mixing volume (131). Break-away cover portions are pistons. Heating is by conduction through cassette from external contact heater. Planar cassette body, when tilted from horizontal, enables upward flow from pumped storage (134, 135) to reaction (133) to waste (139), with buoyancy bubble removal before reaction.

Abstract: The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.

Abstract: Cassette (50) performs assays, e.g. multiplexed protein biomarker assays. Wide, bubble-free, slow flows are produced from liquids stored on cassette (50), flowing over wide array (20) of ligand receptors on a capture surface. Flows of Reynolds Number less than about 1, preferably 1×10?1 to 5×10?3, are heated in region (34) preceding and including bubble removal system (128). Analyte is introduced through compressed septum (32). External actuations of displacement pumps (30, 37) and valves (137 A, B, and C) produce flows in response to flow-front optical sensors (150, 152). Elastic sheet provides pump and valve diaphragms and resilient expansion of mixing volume (131). Break-away cover portions are pistons. Heating is by conduction through cassette from external contact heater. Planar cassette body, when tilted from horizontal, enables upward flow from pumped storage (134, 135) to reaction (133) to waste (139), with buoyancy bubble removal before reaction.

Abstract: The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.